01.12.2017 | Research article | Ausgabe 1/2017 Open Access

A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer
- Zeitschrift:
- BMC Cancer > Ausgabe 1/2017